Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease (NAFLD) is poorly known. We gauged the risk of developing T2D and MetS in patients with NAFLD diagnosed by either serum liver enzymes (am...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of gastroenterology and hepatology Ročník 31; číslo 5; s. 936 - 944
Hlavní autoři:	Ballestri, Stefano, Zona, Stefano, Targher, Giovanni, Romagnoli, Dante, Baldelli, Enrica, Nascimbeni, Fabio, Roverato, Alberto, Guaraldi, Giovanni, Lonardo, Amedeo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Australia Blackwell Publishing Ltd 01.05.2016
Témata:	Alanine Transaminase - blood ALT Aspartate Aminotransferases - blood AST Biomarkers - blood Chi-Square Distribution Clinical Enzyme Tests Diabetes Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology gamma-Glutamyltransferase - blood GGT Humans Incidence Liver enzymes Metabolic Syndrome Metabolic Syndrome - diagnosis Metabolic Syndrome - epidemiology NAFLD Non-alcoholic Fatty Liver Disease - blood Non-alcoholic Fatty Liver Disease - diagnostic imaging Non-alcoholic Fatty Liver Disease - epidemiology Prognosis Risk Assessment Risk Factors Time Factors Ultrasonography AST NAFLD GGT Metabolic Syndrome Ultrasonography ALT Liver enzymes Diabetes
ISSN:	0815-9319, 1440-1746, 1440-1746
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D) and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease (NAFLD) is poorly known. We gauged the risk of developing T2D and MetS in patients with NAFLD diagnosed by either serum liver enzymes (aminotransferases or gamma‐glutamyltransferase [GGT]) or ultrasonography. Methods: Pertinent prospective studies were identified through extensive electronic database research, and studies fulfilling enrolment criteria were included in the meta‐analysis. Results Overall, in a pooled population of 117020 patients (from 20 studies), who were followed‐up for a median period of 5 years (range: 3–14.7 years), NAFLD was associated with an increased risk of incident T2D with a pooled relative risk of 1.97 (95% confidence interval [CI], 1.80–2.15) for alanine aminotransferase, 1.58 (95% CI, 1.43–1.74) for aspartate aminotransferase, 1.86 (95% CI, 1.71–2.03) for GGT (last vs first quartile or quintile), and 1.86 (95% CI, 1.76–1.95) for ultrasonography, respectively. Overall, in a pooled population of 81411 patients (from eight studies) who were followed‐up for a median period of 4.5 years (range: 3–11 years), NAFLD was associated with an increased risk of incident MetS with a pooled relative risk of 1.80 (95% CI, 1.72–1.89) for alanine aminotransferase (last vs first quartile or quintile), 1.98 (95% CI, 1.89–2.07) for GGT, and 3.22 (95% CI, 3.05–3.41) for ultrasonography, respectively. Conclusions: Nonalcoholic fatty liver disease, as diagnosed by either liver enzymes or ultrasonography, significantly increases the risk of incident T2D and MetS over a median 5‐year follow‐up.
Bibliografie:	ark:/67375/WNG-BMQ1W9RV-L istex:E38D9F7BC73B7936559F5F2EBF384C75BE867212 ArticleID:JGH13264 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4
ISSN:	0815-9319 1440-1746 1440-1746
DOI:	10.1111/jgh.13264